Replies to post #627854 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

The fudster-extraordinaire can't seem to keep up with the FDA guidance on the ECAs in the 2022 AOO article. The fudster also can't seem to grasp the idea of crossover and rGBM efficacy. Which shall go with? The JAMA data or the fudster's ramblings?